Description
Calderasib is a KRAS G12C inhibitor used in the treatment of colorectal cancer harboring specific KRAS mutations. It works by selectively targeting and binding to the mutated KRAS G12C protein, which is present in a subset of colorectal tumors.
Mechanism of Action
The drug covalently binds to the cysteine residue in the KRAS G12C mutant protein, locking it in an inactive state. This prevents the aberrant signaling pathways that drive cancer cell proliferation and survival.
Side Effects
Nausea
Diarrhea
Fatigue
Decreased appetite
Vomiting
Constipation
Abdominal pain
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT06997497
med_phase_prefix3
Recruiting
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
United States, Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Fin
NCT07209111
med_phase_prefix2
Archived
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
United States, Australia, Chile, China, Denmark, Germany, Greece, Israel, Italy,